Abstract
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) characterized by localized areas of demyelination1. Although the etiology and pathogenesis of MS remain largely unknown, it is generally assumed that immune responses to myelin antigens contribute to the disease process1,2. The exact sequence of events, as well as the molecular mediators that lead to myelin destruction, is yet to be defined2,3. As a potent mediator of inflammation, the cytopathic cytokine, tumor necrosis factor (TNF) has been considered to be a strong candidate in the pathogenesis of MS and its animal model, experimental autoimmune encephalomyelitis (EAE)3–5. However, its role in immune-mediated demyelination remains to be elucidated. To determine the contribution of TNF to the pathogenesis of the MS-like disease provoked by the myelin oligodendrocyte glycoprotein (MOG)6, we have tested mice with an homologous disruption of the gene encoding TNF (ref. 7). Here we report that upon immunization with MOG, mice lacking TNF develop severe neurological impairment with high mortality and extensive inflammation and demyelination. We show further that inactivation of the TNF gene converts MOG-resistant mice to a state of high susceptibility. Furthermore, treatment with TNF dramatically reduces disease severity in both TNF−/− mice and in other TNF+/+ mice highly susceptible to the MOG-induced disease. These findings indicate that TNF is not essential for the induction and expression of inflammatory and demyelinating lesions, and that it may limit the extent and duration of severe CNS pathology.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Raine, C.S. The immunology of the multiple sclerosis lesion [The Dale E. McFarlin memorial lecture]. Ann. Neurol. 36, S61–S72 (1994).
Bernard, C.C.A. & Kerlero de Rosbo, N. Multiple sclerosis: An autoimmune disease of multifactorial etiology. Curr. Opin. Cell Biol. 4, 760–765 (1992).
Merrill, J.E. & Benveniste, E.N. Cytokines in inflammatory brain lesions: Helpful and harmful. Trends Neurosci. 19, 331–338 (1996).
Navikas, V. & Link, H. Cytokines and the pathogenesis of multiple sclerosis [Review]. J. Neurosci. Res. 45, 322–333 (1996).
Selmaj, K., Papierz, W., Glabinski, A. & Kohno, T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J. Neuroimmunol. 56, 135–141 (1995).
Bernard, C.C.A., et al. Myelin oligodendrocyte glycoprotein: A novel candidate autoantigen in multiple sclerosis. J. Mol. Med. 75, 77–88 (1997).
Marino, M.W., et al. Characterization of tumor necrosis factor deficient mice. Proc. Natl. Acad. Sci. USA 94, 8093–8098 (1997).
Aggarwal, B.B. & Natarajan, K. Tumor necrosis factor: Developments during the last decade. Eur. Cytokine Netw. 7; 93–124 (1996).
Ruddle, N.H. et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172, 1193–1200 (1990).
Willenborg, D.O., Fordham, S., Bernard, C.C.A., Cowden, W.B. & Ramshaw, I.A. IFN-γ plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocy glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157, 3223–3227 (1996).
Ichikawa, M., Johns, T.G., Liu, J. & Bernard, C.C.A. Analysis of the fine B cell specificity during the chronic/relapsing course of a multiple sclerosis-like disease in Lewis rats injected with the encephalitogenic myelin oligodendrocyte glycoprotein peptide 35–55. J. Immunol. 157, 919–926 (1996).
Pasparakis, M., Alexopoulou, L., Episkopou, V. & Kollias, G. Immune and inflammatory responses in TNFα-deficient mice: A critical requirement for TNFα in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184, 1397–1411 (1996).
Linington, C., et al. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur. J. Immunol. 23, 1364–1371 (1993).
Sercarz, E.E., et al. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11, 729–766 (1993).
Selmaj, K., Raine, C.S., Farooq, M., Norton, W.T. & Brosnan, C.F. Cytokine cytotoxicity against oligodendrocytes: Apoptosis induced by lymphotoxin. J. Immunol. 147, 1522–1529 (1991).
Sharief, M.K. & Hentges, R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 325, 467–472 (1991).
Paya, C.V., Leibson, P.J., Patrick, A.K. & Rodriguez, M. Inhibition of Theiler's virus-induced demyelination in vivo by tumor necrosis factor-α. Int. Immunol. 2, 909–913 (1990).
Jacob, C.O. & McDevitt, H.O. Tumour necrosis factor-α in murine autoimmune ‘lupus’ nephritis. Nature, 331, 356–358 (1988).
Jacob, C.O., Aiso, S., Michie, S.A., McDevitt, H.O. & Acha-Orbea, H. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): Similarities between TNF-α and interleukin 1. Proc. Natl. Acad. Sci. USA 87, 968–972 (1990).
Bruce, A.J., et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nature Med. 2, 788–794 (1996).
Rothwell, N.J. & Luheshi, G.N. Brain TNF: Damage limitation or damaged reputation? Nature Med. 2, 746–747 (1996).
Liu, Z., Hsu, H., Goeddel, D.V. & Karin, M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 87, 565–576 (1996).
Eugster, H-P., et al. Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-α double-deficient mice. Int. Immunol. 8, 23–36 (1996).
Lewis, M., et al. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc. Natl. Acad. Sci. USA 88, 2830–2834 (1991).
Vanoosten, B.W., et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody CA2. Neurology 47, 1531–1534 (1996).
Jayaram, B.M., Menon, K.K., Slavin, A., Reid, H. & Bernard, C.C.A. Purification of human myelin oligodendrocyte glycoprotein (MOG) produced in bacteria and Sf9 insect cells [Abstr.]. J. Neurochem. 66, S41 (1996).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liu, J., Marino, M., Wong, G. et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 4, 78–83 (1998). https://doi.org/10.1038/nm0198-078
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0198-078
This article is cited by
-
ROGUE: an R Shiny app for RNA sequencing analysis and biomarker discovery
BMC Bioinformatics (2023)
-
Therapeutic Potential of Cytokines in Demyelinating Lesions After Stroke
Journal of Molecular Neuroscience (2021)
-
Anti-Inflammatory Effects of an Extract from Pseudomonas aeruginosa and Its Purified Product 1-Hydroxyphenazine on RAW264.7 Cells
Current Microbiology (2021)
-
CGRP-Mediated Prolactin Upregulation: a Possible Pathomechanism in IgG4-Related Disease
Inflammation (2021)
-
Neuroinflammation, the thread connecting neurological disease
Acta Neuropathologica (2019)